Notícias e Atividades da Hummingbird Bioscience

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Hummingbird Bioscience

• Piers Ingram, Chief Executive Officer and Executive Director
• Victor Tong, Director
• Kenneth Harrison, Director

Recentes movimentos de executivos em Hummingbird Bioscience

• Dipti Thakkar antes Vice President, Target Biology and Pharmacology, foi promovido a Chief Operating Officer  (Notícia publicada em 3 de junho de 2025).

Criar um alerta
para seguir os movimentos de executivos da Hummingbird Bioscience.

Hummingbird Bioscience possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Hummingbird Bioscience

• News – 2025 | Hummingbird Bioscience
• News – 2019 | Hummingbird Bioscience
• News – 2024 | Hummingbird Bioscience
• Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment | Hummingbird Bioscience
• Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers | Hummingbird Bioscience
• Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. | H
• New biotech facility Hummingbird Bioscience opens | Video
• Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies - Hummingbird Bioscience
• Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers - Hummingbird Bioscience
• News – Hummingbird
• View more press releases Close

Redes sociais sobre Hummingbird Bioscience

• Hummingbird Bioscience na Wikipedia, Google News e Yahoo Finance
• Hummingbird Bioscience na LinkedIn, Twitter e YouTube